Background
Methods
Systematic review
Eligibility criteria
Information sources
Study selection
Meta-analysis
Summary measures and synthesis of results
Risk of bias across studies
Results
Literature search and description of studies
Mapping of lncRNA prognostic data
Characteristic | Subgroups | Frequency (%) |
---|---|---|
Year | 2000–2013 | 13 (12 %) |
2013–2014 | 23 (21 %) | |
2014–2014 | 0 (0 %) | |
2014–2015 | 75 (68 %) | |
N | 111 (100 %) | |
Cancer site | Gastric | 16 (13 %) |
Colorectal | 15 (12 %) | |
Lung | 15 (12 %) | |
Brain | 12 (9 %) | |
Esophageal | 10 (8 %) | |
Prostate | 10 (8 %) | |
Hepatic | 9 (7 %) | |
Breast | 6 (5 %) | |
Pancreatic | 6 (5 %) | |
Cervical | 5 (4 %) | |
Head and neck | 4 (3 %) | |
Ovarian | 4 (3 %) | |
Renal | 4 (3 %) | |
Urinary bladder | 4 (3 %) | |
Any | 2 (2 %) | |
Hematologic | 2 (2 %) | |
Endometrial | 1 (1 %) | |
GIST | 1 (1 %) | |
Neuroblastoma | 1 (1 %) | |
N | 127 (100 %) | |
Agnostic a
| No | 85 (77 %) |
Yes | 21 (19 %) | |
Agnostic parent | 5 (5 %) | |
N | 111 (100 %) | |
Survival analysis | OS | 92 (83 %) |
RFS | 36 (32 %) | |
DSS | 10 (9 %) | |
MFS | 9 (8 %) | |
PFS | 6 (5 %) | |
N | 111 (100 %) | |
Quantification method | qRT-PCR | 84 (66 %) |
ISH | 28 (22 %) | |
qPCR | 11 (9 %) | |
qRT-PCR or ISH | 2 (2 %) | |
RT-qPCR | 1 (1 %) | |
Unreported | 1 (1 %) | |
N | 127 (100 %) | |
Continent | Asia | 94 (74 %) |
Europe | 15 (12 %) | |
America | 13 (10 %) | |
Multiple | 3 (2 %) | |
Unreported | 2 (2 %) | |
N | 127 (100 %) | |
Study design | Unreported | 106 (83 %) |
Retrospective | 19 (15 %) | |
Prospective | 2 (2 %) | |
N | 127 (100 %) | |
Sampling method | Unreported | 113 (89 %) |
Consecutive | 5 (4 %) | |
Population | 5 (4 %) | |
Random | 4 (3 %) | |
N | 127 (100 %) | |
Tissue preservation b
| L | 66 (52 %) |
Unreported | 34 (27 %) | |
P | 18 (14 %) | |
LP | 6 (5 %) | |
L + RNALater | 3 (2 %) | |
N | 127 (100 %) | |
Pre-biopsy treatment | No | 77 (61 %) |
Unreported | 46 (36 %) | |
Yes | 4 (3 %) | |
N | 127 (100 %) | |
Post-biopsy treatment | Unreported | 98 (77 %) |
Yes | 27 (21 %) | |
No | 2 (2 %) | |
N | 127 (100 %) | |
Total number of lncRNAs studied | 1 | 87 (78 %) |
2–10 | 4 (4 %) | |
11–45033 | 15 (14 %) | |
Unreported | 5 (5 %) | |
N | 111 (100 %) | |
Outcomes | Clinical and Non-clinical | 76 (68 %) |
Clinical only | 35 (32 %) | |
N | 111 (100 %) | |
Use of validation method for survival | Unreported | 99 (89 %) |
External | 5 (5 %) | |
Internal | 4 (4 %) | |
Both | 2 (2 %) | |
Yes | 1 (1 %) | |
N | 111 (100 %) |
Overall survival
LncRNA | Times studied | Number of cancer types (sample size) | Median (IQR) | Times significant (%) |
---|---|---|---|---|
HOTAIR | 29 | 13 (3886) | 100 (69) | 28 (97 %) |
MALAT1 | 8 | 7 (1135) | 136 (53) | 5 (62 %) |
H19 | 4 | 2 (440) | 77 (57) | 2 (50 %) |
PVT1 | 4 | 4 (420) | 87 (24) | 4 (100 %) |
GAS5 | 4 | 4 (369) | 96 (19) | 4 (100 %) |
SChLAP1 | 3 | 1 (1396) | 357 (440) | 3 (100 %) |
6 lncRNA risk score | 3 | 1 (281) | 42 (94) | 1 (33 %) |
CCAT2 | 2 | 2 (1226) | 613 (384) | 1 (50 %) |
LncR1 vs LncR2 vs LncR3 | 2 | 1 (759) | 380 (96) | 2 (100 %) |
ENSG00000261582 | 2 | 2 (576) | 288 (199) | 2 (100 %) |
MVIH | 2 | 2 (257) | 128 (86) | 2 (100 %) |
LOC285194 | 2 | 2 (227) | 114 (28) | 2 (100 %) |
PCAT1 | 2 | 2 (212) | 106 (2) | 2 (100 %) |
SPRY4-IT1 | 2 | 2 (190) | 95 (3) | 2 (100 %) |
UCA1 | 2 | 2 (170) | 85 (5) | 2 (100 %) |
GHET1 | 2 | 2 (122) | 61 (19) | 2 (100 %) |
MEG3 | 2 | 2 (116) | 58 (14) | 2 (100 %) |
Meta-analysis for overall survival
LncRNA | Studies | HR (95 % CI) |
P-value | I2 (95 % CI) | Observed (Expected, p-value) |
---|---|---|---|---|---|
HOTAIR | 26 | 2.22 (1.86–2.65) | 0.0000 | 49 % (14–79 %) | 25 (18.2, p-value = 0.002) |
MALAT1 | 7 | 2.03 (1.64–2.52) | 0.0000 | 0 % (0–85 %) | 5 (4.1, p-value = 0.707) |
6 lncRNA risk score | 4 | 1.57 (1.29–1.92) | 0.0000 | 0 % (0–47 %) | 2 (2.1, p-value = 1.000) |
GAS5 | 4 | 0.81 (0.33–2.00) | 0.6479 | 94 % (80–100 %) | 4 (2.1, p-value = 0.128) |
H19 | 4 | 1.16 (1.04–1.29) | 0.0100 | 0 % (0–98 %) | 2 (0.8, p-value = 0.170) |
PVT1 | 4 | 2.99 (2.10–4.27) | 0.0000 | 0 % (0–56 %) | 4 (2.7, p-value = 0.309) |
SChLAP1 | 3 | 1.98 (1.55–2.54) | 0.0000 | 0 % (0–98 %) | 3 (2.9, p-value = 1.000) |